Use of patient-derived explants as a preclinical model for precision medicine in colorectal cancer: A scoping review
- Author(s)
- Mui, M; Clark, M; Vu, TMSH; Clemons, N; Hollande, F; Roth, S; Ramsay, R; Michael, M; Heriot, AG; Kong, JCH;
- Journal Title
- Langenbeck's Archives of Surgery
- Publication Type
- Review
- Abstract
- PURPOSE: Whilst the treatment paradigm for colorectal cancer has evolved significantly over time, there is still a lack of reliable biomarkers of treatment response. Treatment decisions are based on high-risk features such as advanced TNM stage and histology. The role of the tumour microenvironment, which can influence tumour progression and treatment response, has generated considerable interest. Patient-derived explant cultures allow preservation of native tissue architecture and tumour microenvironment. The aim of the scoping review is to evaluate the utility of patient-derived explant cultures as a preclinical model in colorectal cancer. METHODS: A search was conducted using Ovid MEDLINE, EMBASE, Web of Science, and Cochrane databases from start of database records to September 1, 2022. We included all peer-reviewed human studies in English language which used patient-derived explants as a preclinical model in primary colorectal cancer. Eligible studies were grouped into the following categories: assessing model feasibility; exploring tumour microenvironment; assessing ex vivo drug responses; discovering and validating biomarkers. RESULTS: A total of 60 studies were eligible. Fourteen studies demonstrated feasibility of using patient-derived explants as a preclinical model. Ten studies explored the tumour microenvironment. Thirty-eight studies assessed ex vivo drug responses of chemotherapy agents and targeted therapies. Twenty-four studies identified potential biomarkers of treatment response. CONCLUSIONS: Given the preservation of tumour microenvironment and tumour heterogeneity, patient-derived explants has the potential to identify reliable biomarkers, treatment resistance mechanisms, and novel therapeutic agents. Further validation studies are required to characterise, refine and standardise this preclinical model before it can become a part of precision medicine in colorectal cancer.
- Publisher
- Springer Nature
- Keywords
- Humans; Precision Medicine; *Antineoplastic Agents/therapeutic use; Biomarkers; *Colorectal Neoplasms/drug therapy/genetics; Tumor Microenvironment
- Department(s)
- Surgical Oncology; Laboratory Research; Medical Oncology
- PubMed ID
- 37816905
- Publisher's Version
- https://doi.org/10.1007/s00423-023-03133-7
- Open Access at Publisher's Site
https://doi.org/10.1007/s00423-023-03133-7- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2023-12-05 12:35:35
Last Modified: 2023-12-05 12:50:03